Efficient transfection of blood-brain barrier endothelial cells by lipoplexes and polyplexes in the presence of nuclear targeting NLS-PEG-acridine conjugates.

Brain capillary endothelial cells of the blood-brain barrier (BBB) are difficult targets for nonviral transfection even for the most potent transfection agents. Efficient protection and nuclear delivery of plasmid DNA are the key requirements for enhancing the transfection. We designed novel DNA intercalating conjugates of PEG-tris(acridine) with a short nuclear localization signal (NLS) peptide and investigated the effect of their complexes with luciferase-encoded plasmid DNA on lipoplex- and polyplex-mediated transfection of murine brain capillary endothelial bEnd.3 cells. These intercalation complexes protected DNA from nucleolytic degradation forming a protective PEG layer around plasmid DNA and could be efficiently condensed by Lipofectamine2000 or Exgen500 into nanosized particles. Complexation of plasmid DNA with a PEG-acridine/NLS-PEG-acridine mixture (9:1 w/w), taken in an amount equal to 5-6 NLS peptides per DNA molecule, significantly enhanced both lipo- and polyplex transfection efficacies and increased the number of transfected bEnd.3 endothelial cells in the presence of serum. Comparative transgene expression efficiency was significantly higher at longer PEG linker and optimal conjugate-to-DNA weight ratio, especially, at lower N/P ratio for both transfection agents, reaching 15-16-fold for lipoplexes and 10-11-fold for polyplexes. In addition, the NLS-PEG-acridine conjugates did not increase cytotoxicity of lipoplexes and polyplexes to bEnd.3 cells. These conjugates can serve as promising components for development of systemic nonviral transfecting approach to the transfection of the BBB and temporary modulation of its drug permeability.

Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.

The therapeutic efficiency of anticancer nucleoside analogues (NA) strongly depends on their intracellular accumulation and conversion into 5'-triphosphates. Because active NATP cannot be directly administrated due to instability, we present here a strategy of nanoencapsulation of these active drugs for efficient delivery to tumors. Stable lyophilized formulations of 5'-triphosphates of cytarabine (araCTP), gemcitabine (dFdCTP), and floxuridine (FdUTP) encapsulated in biodegradable PEG-cl-PEI or F127-cl-PEI nanogel networks (NGC and NGM, respectively) were prepared by a self-assembly procedure. Cellular penetration, in vitro cytotoxicity, and drug-induced cell cycle perturbations of these nanoformulations were analyzed in breast and colorectal cancer cell lines. Cellular accumulation and NATP release from nanogel was studied by confocal microscopy and direct high-performance liquid chromatography analysis of cellular lysates. Antiproliferative effect of dFdCTP nanoformulations was evaluated in human breast carcinoma MCF7 xenograft animal model. Nanoencapsulated araCTP, dFdCTP, and FdUTP showed similar to NA cytotoxicity and cell cycle perturbations. Nanogels without drugs showed very low cytotoxicity, although NGM was more toxic than NGC. Treatment by NATP nanoformulations induced fast increase of free intracellular drug concentration. In human breast carcinoma MCF7 xenograft animal model, i.v. dFdCTP-nanogel was equally effective in inhibiting tumor growth at four times lower administered drug dose compared with free gemcitabine. Active triphosphates of NA encapsulated in nanogels exhibit similar cytotoxicity and cell cycle perturbations in vitro and faster cell accumulation and equal tumor growth-inhibitory activity in vivo at much lower dose compared with parental drugs, illustrating their therapeutic potential for cancer chemotherapy.